BPC-157 Dosage Calculator & Reconstitution Guide

Use the calculator to understand concentration and volume, then see what early BPC-157 studies do—and do not—establish about dosing. The guide retains worked examples, a clearly labeled weight-formula illustration and practical preparation questions without presenting an experimental regimen as established care.

Standard Dosage Guidelines

The previously displayed 5–10 mcg/kg daily formula is not a validated general-purpose human BPC-157 regimen in the studies reviewed here. A weight-based calculation can be arithmetically correct without identifying an effective dose, route or duration.

Early human signal: Lee and Padgett’s retrospective knee-pain report contacted 16 of 17 recipients; 11 of the 12 who received BPC-157 alone reported improvement. The treatment was intra-articular, not a daily subcutaneous protocol. Without a randomized comparison or standardized functional assessment, this encouraging observation does not validate a body-weight dosing formula.

Short-term tolerability signal: Lee and Burgess’s intravenous pilot studied two previously exposed adults given 10 mg on day one and 20 mg on day two, with follow-up measurements on day three. No adverse effects or changes in the tested biomarkers were reported. These study exposures are not a home-use recommendation, an overdose threshold or evidence that higher doses work better.

How to read reported protocols: keep the molecule, formulation, route, population and outcome attached to each claim. An individual’s experience can be useful context, but cannot identify an optimal range for most users or a reliable week-six escalation rule.

The weight chart below illustrates the page’s former formula for arithmetic transparency, not prescribing. The calculator similarly needs an amount supplied by the user; its default example is not a recommended BPC-157 dose.

Condition-Specific Dosing

Different research questions should not be collapsed into one dosing schedule. The following separates the conditions discussed on this page from the level of evidence available; it is not a condition-to-dose lookup table.

General wellness & preventative: the cited human reports did not test prevention in otherwise healthy people or establish a daily wellness dose. A personal report of feeling better can be retained as anecdotal experience, not proof of a preventive benefit.

Acute injury (first 4 weeks): Krivic and colleagues’ rat Achilles-detachment study reported improved tendon-to-bone healing. This preclinical signal does not establish a four-week human loading phase or show that increasing a home dose accelerates healing.

Chronic pain or structural issues: the encouraging knee-pain series above concerns clinician-administered joint injections and subjective outcomes. It does not establish an eight-to-twelve-week daily regimen or demonstrate structural repair across different pain diagnoses.

GI issues & leaky gut: the PCO-02 oral trial registration describes a planned safety and pharmacokinetic investigation in healthy volunteers, not a validated oral or nasal treatment for these symptoms. A trial registration is not proof of efficacy; formulation and clinical results matter.

Tendon/ligament injuries: Cerovecki and colleagues’ rat ligament study supports continued repair research. It does not establish that injecting near a human injury works better, or authorize a home injection into a tendon, ligament or joint.

Post-surgical recovery: an experimentally created animal injury is not a postoperative human dosing trial. The surgeon should coordinate recovery care; the cited evidence does not establish immediate postoperative BPC-157 initiation or a dose-dependent recovery advantage in people.

Reconstitution & Math Formulas

Concentration is the total amount divided by the final solution volume. It determines the volume corresponding to a specified amount, not the preparation’s storage life or a clinically appropriate BPC-157 dose.

Illustrative concentration, not a mixing recommendation: 1 mg is 1,000 mcg. If the verified final solution volume is 4 mL, the concentration is 250 mcg/mL.

Formula: total amount (mg) × 1,000 ÷ final solution volume (mL) = concentration (mcg/mL).

Why this works: 1,000 mcg ÷ 4 mL = 250 mcg/mL. Do not assume the volume of diluent added always equals the final solution volume, or that a vial can hold any calculated volume.

Alternative arithmetic: 1 mg in a final volume of 10 mL gives 100 mcg/mL; 1 mg in a final volume of 2 mL gives 500 mcg/mL. These are mathematical examples, not evidence that either preparation is suitable or more comfortable to inject.

Diluent and storage: follow the exact preparation’s written instructions for compatible diluent, final concentration, handling and beyond-use date. The Hospira bacteriostatic-water label cautions that drug compatibility and storage after mixing depend on the drug’s instructions. It does not establish an eight-to-twelve-week BPC-157 shelf life. Preservatives do not eliminate contamination risk; see CDC injection-safety guidance.

Calculating Your Injection Volume

Once a specified amount and verified concentration are known, the volume calculation is straightforward. Choosing that amount and deciding whether the volume is appropriate are separate clinical and device questions.

Desired dose (mcg) ÷ Concentration (mcg/mL) = Injection volume (mL)

Example 1: 500 mcg ÷ 250 mcg/mL = 2.0 mL. This exceeds the capacity of a 1 mL syringe; the earlier instruction to draw it in an unspecified insulin syringe was incomplete. Do not select a larger syringe or split an injection solely to make a calculator result fit.

Example 2: 600 mcg ÷ 100 mcg/mL = 6.0 mL. Although the division is correct, this does not make a 6 mL injection appropriate. Confirm the preparation, intended route and volume with the treating clinician or dispensing pharmacy rather than following the former generic 10 mL-syringe instruction.

Example 3: 400 mcg ÷ 500 mcg/mL = 0.8 mL. Device capacity and marking precision still need checking. Syringe markings represent volume; they are not interchangeable with mcg or mg of peptide.

Dosage Timing & Frequency

He and colleagues’ pharmacokinetic study found an elimination half-life under 30 minutes for the parent peptide after the studied IV/IM administrations in rats and beagle dogs. This is animal pharmacokinetic evidence, not a measured human subcutaneous half-life or a validated injection schedule. Persistence of a biological effect is a separate question from how quickly circulating parent peptide declines.

Once daily: the human reports summarized above did not test a daily home-injection regimen. The former claim that 90% of users find it effective was not backed by a cited survey or trial.

Twice daily: splitting the same total amount changes the schedule, but comparative human evidence cited here does not show faster healing. Do not infer a need to redose from the animal half-life alone.

Pre-workout dosing: an optimal 30–60-minute window has not been established by the human studies cited here. Symptom improvement does not by itself establish tissue healing or readiness for heavier training.

Quick Reference Dosage Chart

These are illustrative multiplications of the former, unvalidated formula—not recommended doses. Pounds are converted to kilograms and rounded to the nearest whole kilogram first; each result below uses that displayed kilogram value. Rounding is for this arithmetic illustration, not a dosing instruction.

The numbers above do not establish a useful dose range or an 800 mcg/day benefit ceiling. They show how a formula behaves, not whether the formula has clinical validity.

Cycling Protocols for Long-Term Use

A cycle describes a schedule, not evidence that the schedule prevents tolerance. The short IV pilot and retrospective knee report cited above did not compare long-term on/off regimens. They cannot establish a maintenance plan or the safety of indefinite use.

Standard Cycle: the former eight-weeks-on/four-weeks-off example was not validated by the cited human studies. It should not be described as preventing adaptation.

Extended Cycle: a twelve-week course is not proven to produce stronger results than a shorter course in the evidence reviewed here. Persistent symptoms warrant reassessment of the diagnosis and recovery plan, not an automatic extension.

Maintenance Cycle: no indefinite maintenance regimen was established by the cited studies. Keep anecdotal cycle descriptions separate from a clinician’s plan and from evidence of durable benefit.